Spots Global Cancer Trial Database for fp1039
Every month we try and update this database with for fp1039 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling | NCT01868022 | Neoplasms | GSK3052230 paclitaxel carboplatin docetaxel pemetrexed cisplatin | 18 Years - | GlaxoSmithKline | |
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling | NCT01868022 | Neoplasms | GSK3052230 paclitaxel carboplatin docetaxel pemetrexed cisplatin | 18 Years - | GlaxoSmithKline | |
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling | NCT01868022 | Neoplasms | GSK3052230 paclitaxel carboplatin docetaxel pemetrexed cisplatin | 18 Years - | GlaxoSmithKline |